GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolys BioPharma Inc (TSE:4588) » Definitions » YoY EBITDA Growth

Oncolys BioPharma (TSE:4588) YoY EBITDA Growth : 2.49% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Oncolys BioPharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Oncolys BioPharma's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 2.49%.

Oncolys BioPharma's EBITDA per Share for the three months ended in Mar. 2024 was 円-18.13.


Oncolys BioPharma YoY EBITDA Growth Historical Data

The historical data trend for Oncolys BioPharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolys BioPharma YoY EBITDA Growth Chart

Oncolys BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.62 -123.35 34.58 30.42 -64.64

Oncolys BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 -126.79 -46.67 -87.86 2.49

Oncolys BioPharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Oncolys BioPharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-108.428--65.859)/ | -65.859 |
=-64.64 %

Oncolys BioPharma's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-18.134--18.598)/ | -18.598 |
=2.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncolys BioPharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Oncolys BioPharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolys BioPharma (TSE:4588) Business Description

Traded in Other Exchanges
N/A
Address
4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is engaged in research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agents.

Oncolys BioPharma (TSE:4588) Headlines

No Headlines